Cigna Group continues to show strong earnings and has raised its adjusted EPS guidance for 2026 to at least $30.60, targeting 10% EPS growth in 2027. While the healthcare segment's margins improved, the pharmacy benefit management (PBM) segment faces challenges from contract renewals, rebate compression, and regulatory risks. However, strong contract wins and retention, along with capital returns, cost savings, and revenue growth, support confidence that the company's upside potential outweighs the risks at current valuations.
Cigna Corp trades at USD 295.50 on Pluang as of Nov 06, 2026 22:41 WIB, down 1.98% in one day. The stock's market cap stands at $79.66 billion with a dividend yield of 2.07%. Despite recent price pressure, typical hold time on Pluang is 67 days, indicating moderate investor confidence.
